Navigation
banner

Diabetes Summit

2018-01-232018-02-272018-01-19
EARLY BIRD DISCOUNT! Register by Feb 27, 2018 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 detailed agenda is currently being formed.

Please come back and visit this page for updates.

BELOW IS THE DETAILED AGENDA FROM 2017.

ssclaas=mixsessionprlval=1Array ( [316] => 1 )
Day 1 - Wednesday, April 5, 2017
7:30
Continental Breakfast & Registration
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
8:15
Opening Remarks
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
10:00
Morning Networking Break
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
Diabetes Drug Discovery & Development 2017
Going Back to the Basics – Street Light Effect
Moderator: Larry Steinman, Stanford University
10:30
Antigen Specific Tolerance for Type 1 Diabetes
 
Larry Steinman
Larry Steinman
Professor, Pediatrics and Neurology
Stanford University
About Speaker: Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in multiple sclerosis (MS... Read Full Bio 
 
 
Larry Steinman
Larry Steinman
Professor, Pediatrics and Neurology
Stanford University
 
About Speaker:

Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in multiple sclerosis (MS) and in neuromyelitis optica (NMO) and the quest for antigen specific therapy. He and colleagues have advanced an antigen specific therapy in type 1 diabetes to Phase 2b.  He is also developing a small molecule therapeutic in trials for Huntington’s Disease. Steinman identified guardian molecules in brain that have protective properties in a number of inflammatory conditions.  These protective molecules activate regulatory B cells. 

Steinman was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s disease.

Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School.  He was a post-doctoral fellow in chemical immunology fellow at the Weizmann Institute of Science. After neurology residency he remained on the faculty in 1980.  He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, the Charcot Prize in MS research, and the Cerami Prize in Translational Medicine. Steinman is a member of the National Academy of Sciences, and the National Academy of Medicine.

 
Abstract: We know ...Read More 

We know the key components that are targeted by adaptive immunity in type 1 diabetes.  Why are attempts at antigen specific tolerance so rarely taken into the clinic.  A phase 2A trial with a plasmid engineered to tolerize to proinsulin was completed in a multi-center placebo controlled trial.  There was a rise in C-peptide during the period of 12 weekly doses, with a concomitant lowering of HgbA1c.  Quantum dot studies using flow cytometry indicate that as C-peptide increased, CD8 T cells specific for proinsulin fell. There were no changes in CD8 T cells to other islet antigens or to viral antigens.  A Phase 2b study will be presented as we continue progress on this front.  The promise of antigen specific tolerance in type 1 diabetes will be discussed in relationship to other ongoing programs across the globe.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
11:10
Technology in Science Does Not Always Bring innovation and Discovery; The Human Factor is the Key to Success
 
Bruno Doiron
Bruno Doiron
Assistant Professor
University of Texas Health Science Center at San Antonio
About Speaker: Bruno Doiron, Ph.D is a faculty member at the University of Texas Health Science at San Antonio. He received his undergraduate degree from University of Moncton, N.B. Canada and graduate degrees from University of Montreal, QC, Canada and University ... Read Full Bio 
 
 
Bruno Doiron
Bruno Doiron
Assistant Professor
University of Texas Health Science Center at San Antonio
 
About Speaker:

Bruno Doiron, Ph.D is a faculty member at the University of Texas Health Science at San Antonio. He received his undergraduate degree from University of Moncton, N.B. Canada and graduate degrees from University of Montreal, QC, Canada and University of Paris Descartes, Paris, France. As project leader he has made major discoveries in the field of gene regulation by nutrients and has 4 patents on the modulation of glucose metabolism as it relates to the treatment diabetes and cancer. Dr. Doiron has extensive experience in basic research at the physiologic and molecular levels and in respective applications to the biotechnology field.    

 
Abstract: The stre...Read More 

The street light effect in science is enhanced by today’s technology. Today’s fascination for new techniques precedes the scientific thinker. Technical skills have become the primary reason the institutions seeks to hire scientists. The researcher does not think by themselves now; the institution gives them a strategic guide to follow for professional advancement in research. Nevertheless, scientific discovery is not reducible to the technique. Scientific discovery only happens in the context of new ideas and concepts. Technology is the instrument used to produce data, but data alone has no meaning. Big data is brilliant at detecting a correlation. Technology is a tool, not dicta trapping minds on one path. More often mapping, sequencing, proteomic core collecting data is based on determined goals imposed by institutional research and only finds what is already known. Technique prevails over novelty. Another set of thinking is needed to integrate the data knowledge produced by the technique into innovation.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
11:40
Preclinical Implication for the Cross-Regulation of Immunity and Type 2 Diabetes
 
Jongsoon Lee
Jongsoon Lee
Assistant Professor of Medicine
Joslin Diabetes Center, Harvard Medical School
About Speaker: Jongsoon Lee, Ph.D., is an Assistant Investigator in the Section on Pathophysiology and Molecular Pharmacology at the Joslin, and an Assistant Professor of Medicine at Harvard Medical School.  Dr. Lee received his BS and MS degrees from Seoul Nation... Read Full Bio 
 
 
Jongsoon Lee
Jongsoon Lee
Assistant Professor of Medicine
Joslin Diabetes Center, Harvard Medical School
 
About Speaker:

Jongsoon Lee, Ph.D., is an Assistant Investigator in the Section on Pathophysiology and Molecular Pharmacology at the Joslin, and an Assistant Professor of Medicine at Harvard Medical School.  Dr. Lee received his BS and MS degrees from Seoul National University in Korea. He received his Ph.D. in Biochemistry from Boston University School of Medicine. 

 
Abstract: Obesity ...Read More 

Obesity is the major cause of the development of insulin resistance and Type 2 Diabetes. Recently, the notion that obesity-induced inflammation mediates the development of insulin resistance in animal models and humans has been gaining strong support. Furthermore, numerous studies have also shown that immune cells in local tissues, in particular in visceral adipose tissue, play a major role in the regulation of obesity-induced inflammation. It has been shown that obesity disrupts the immune balance by suppressing anti-inflammatory cells (e.g., regulatory T cells [Tregs]) while simultaneously activating pro-inflammatory cells (e.g., adipose tissue macrophages [ATMs]). Many studies from the classical immunology field show that complex cross-regulating interactions between different immune cell types control inflammation. However, the roles these interactions play have not been studied extensively in the metabolism field. We have recently shown that natural killer (NK) cells play a critical role in the development of obesity-induced inflammation and insulin resistance, in part by controlling ATM activation and adipose tissue inflammation. Hence, our studies may provide important preclinical evidence for the notion that obesity-induced inflammation regulated by adipose NK cells could be a therapeutic target for the treatment of insulin resistance and Type 2 Diabetes.

 Read Less
ssclaas=parallelprlval=0Array ( [316] => 2 )
11:40
Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications
Judith Gorski
Judith Gorski
Global Director, Scientific Engagement
Crown Bioscience Inc.
 
Judith Gorski
Judith Gorski
Global Director, Scientific Engagement
Crown Bioscience Inc.
 
About Speaker:

Dr. Judith Gorski is Global Director of Scientific Engagement at Crown Bioscience Inc., and is a pharmacologist with over 18 years of experience in drug discovery and development in a large pharmaceutical environment.  She has extensive experience in basic research and targeted drug discovery in the disease areas of type 1 and 2 diabetes, dyslipidemia, atherosclerosis, obesity, and metabolic syndrome.  Dr. Gorski has co-authored publications in Nature, Obesity, Obesity Research, Cell Metabolism, Journal of Lipid Metabolism.

Prior to joining CrownBio, Dr. Gorski’s work at Merck focused on target identification/validation and small molecule and biologics identification/optimization with the aim of recommending lead candidates for clinical development. Her primary responsibilities were to establish and validate appropriate primary, secondary and tertiary in vivo models of dyslipidemia, obesity, metabolic syndrome, and type 1 and 2 diabetes. In addition to preclinical work, Dr. Gorski has been a member of early development teams to move lead candidates into development and has collaborated across an array of disciplines, including drug safety and metabolism, pharmaceutical sciences, early clinical development, medical affairs, regulatory affairs, and commercial development.

Dr. Gorski received her Ph.D. in Neuroscience from University of Medicine and Dentistry, New Jersey.

ssclaas=mixsessionprlval=1Array ( [316] => 1 )
Diabetes Drug Discovery & Development 2017
Novel Therapeutic Targets & Strategies
Moderator: Felicia Pagliuca, Semma Therapeutics
1:25
Is Fibroblast Activation Protein a Target for Treating Type-2 Diabetes
 
William Bachovchin
William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
About Speaker: Dr. Bachovchin serves as Executive Vice President and Chief Scientist and member of the board of directors of Arisaph pharmaceuticals since he co-founded the company in 1999. He was also a co-founder of Point Therapeutics which was a publically trade... Read Full Bio 
 
 
William Bachovchin
William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
 
About Speaker:

Dr. Bachovchin serves as Executive Vice President and Chief Scientist and member of the board of directors of Arisaph pharmaceuticals since he co-founded the company in 1999. He was also a co-founder of Point Therapeutics which was a publically traded biotechnology company prior to its merger with Dara BioSciences. Dr. Bachovchin is also Professor of Biochemistry at Tufts University School of Medicine.

Dr Bachovchin received a BS degree in Biology from Wake Forest University a doctoral degree in Chemistry from The California Institute of Technology, and did postdoctoral work at Harvard Medical School before arriving at Tufts. Dr. Bachovchin is an author on more than 100 peer reviewed journal articles, and an inventor on more than 30 issued patents as well as numerous pending applications. Dr. Bachovchin is a leader in the areas of NMR spectroscopy, enzymes mechanisms and drug design and discovery, especially in areas pertaining to the post proline cleaving family of enzymes. To date three drugs designed by Dr. Bachovchin have entered human clinical trials and several more are in late stage preclinical testing.

 
Abstract: Fibrobla...Read More 

Fibroblast Activating Protein (FAP) is post proline cleaving serine protease with sequence, three dimensional structure and substrate specificity very similar to that of dipeptidyl amino peptidase type 4 (DPP4), which is a validated target for the treatment of diabetes.  Although FAP resembles DPP4 in ability to cleave GLP-1, this activity does not seem to be as biologically significant for FAP as for DPP4, perhaps because FAP occurs in much lower amounts than DPP4.   Recently, FAP has been reported to cleave and limit the lifetime of human, but not mouse FGF-21, suggesting that FAP inhibitors should have anti diabetic activity in humans, even if perhaps not in mice.  However, new evidence indicates that FAP may also function to limit the lifetime of mouse FGF-21 through a different cleavage and mechanism than for human FGF-21. That an FAP knockout mouse has been reported to have improved glucose tolerance, resistance to diet induced obesity and resistance to dyslipidemia, lends some support to the mouse FGF-21 hypothesis, but also that it could be limiting the lifetime of other anti diabetic peptides that could make it a new target for the treatment of type 2 diabetes.  This talk will review and critically evaluate the existing evidence implicating FAP as such a target and present some new results that test this hypothesis.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
1:50
Targeting Islet Amyloid Polypeptide (IAPP) as an Immunotherapy For Type 2 Diabetes
 
Robin Barbour
Robin Barbour
Senior Director Antibody and Assay Development
Prothena Biosciences Inc.
About Speaker: Robin has over 25 years of experience developing antibodies for both misfolded proteins and cell adhesion molecules. Currently two of these mAbs are in clinical trials, NEOD001 for AL amyloidosis and PRX002 for Parkinson’s Disease. Previously at El... Read Full Bio 
 
 
Robin Barbour
Robin Barbour
Senior Director Antibody and Assay Development
Prothena Biosciences Inc.
 
About Speaker:

Robin has over 25 years of experience developing antibodies for both misfolded proteins and cell adhesion molecules. Currently two of these mAbs are in clinical trials, NEOD001 for AL amyloidosis and PRX002 for Parkinson’s Disease. Previously at Elan, her group developed the murine version of Tysabri for Multiple Sclerosis, and Bapineuzumab for Alzheimers. In addition to antibody development, Robin’s group is responsible for the development of assays to support clinical trials including pK, ADA, Biomarker and cell based potency assays.

 
Abstract: Type 2 Diabetes is the most common fo...Read More 

Type 2 Diabetes is the most common form of diabetes and affects 422 million patients worldwide, with little sign of a slowing epidemic, and while there are several classes of anti-diabetic medications available, none are disease modifying. Islet Amyloid Polypeptide (IAPP) is a 37 amino acid peptide that is co-secreted with insulin and is very prone to aggregation. IAPP deposits are found in a majority type 2 diabetes pancreata and the toxicity of insoluble and soluble aggregates are believed to contribute to the pathophysiology of type 2 diabetes. Immunotherapy studies were conducted in a transgenic rat expressing human IAPP, which presents type 2 diabetes-relevant phenotypes such as loss of pancreatic beta-cells and IAPP deposition. We first evaluated the effects of active immunization with IAPP and found even modest titers to IAPP appeared to both decrease number of animal deaths and slow the progression of the disease. Passive immunotherapy was then investigated with three antibodies targeting IAPP. IAPP immunotherapy showed significant effects on slowing increases in hemoglobin A1c and lessening changes in the Oral Glucose Tolerance Test (OGTT) compared to isotype control treated animals. Additionally, we observed decreased extracellular amyloid deposits and a trend to decreased loss of β-cells with one of the antibodies.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
2:15
Novel Mediators of Diabetes Associated Atherosclerosis
 
Sudha Biddinger
Sudha Biddinger
Associate Professor of Pediatrics
Children's Hospital of Boston
About Speaker: Dr. Biddinger is an Associate Professor of Pediatrics at Boston Children’s Hospital/Harvard Medical School.  Her lab is focused on identifying novel targets of insulin that are relevant to the development of dyslipidemia, atherosclerosis and fatty... Read Full Bio 
 
 
Sudha Biddinger
Sudha Biddinger
Associate Professor of Pediatrics
Children's Hospital of Boston
 
About Speaker:

Dr. Biddinger is an Associate Professor of Pediatrics at Boston Children’s Hospital/Harvard Medical School.  Her lab is focused on identifying novel targets of insulin that are relevant to the development of dyslipidemia, atherosclerosis and fatty liver disease in the insulin resistant states of obesity and diabetes. 

Dr. Biddinger performed her undergraduate studies at Princeton University and obtained her MD/PhD from the Johns Hopkins School of Medicine.  She completed her internship, pediatrics residency, and fellowship in pediatric endocrinology at Boston Children’s Hospital. 

 
Abstract: Using mi...Read More 

Using microarray and metabolomics approaches, we have identified the enzyme flavin mono-oxygenase 3 (FMO3) and its product trimethylamine-N-oxide (TMAO) as novel targets of insulin.  In the absence of normal insulin signaling, FMO3 and TMAO are increased.  We further show that knockdown of FMO3 prevents the development of hyperglycemia, hypercholesterolemia and atherosclerosis in insulin resistant mice.  These data suggest that the FMO3/TMAO pathway may yield novel targets for the treatment of diabetes, and the prevention of its complications. 

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
2:40
Specialized Pro-Resolving Mediators: Novel Lipid Mediators in the Resolution Of Inflammation
 
Raja-Elie Abdulnour
Raja-Elie Abdulnour
Instructor of Medicine
Brigham and Women's Hospital
About Speaker: Raja-Elie Abdulnour is a physician-scientist faculty member at Harvard Medical School and the Pulmonary and Critical Care Division of the Brigham and Women's Hospital. His research interests are centered on essential fatty acid-derived Specialized Pr... Read Full Bio 
 
 
Raja-Elie Abdulnour
Raja-Elie Abdulnour
Instructor of Medicine
Brigham and Women's Hospital
 
About Speaker:

Raja-Elie Abdulnour is a physician-scientist faculty member at Harvard Medical School and the Pulmonary and Critical Care Division of the Brigham and Women's Hospital. His research interests are centered on essential fatty acid-derived Specialized Pro-resolving Mediators (SPM) and their role in host defense and resolution of inflammation. He is an investigator in a NIH-funded program project grant led by Prof Charles Serhan that aims to harness SPMs and the recently discovered bioactive SPM-sulfido conjugates for resolution pharmacology. The over-arching goal is to develop novel therapies to better treat human diseases defined by uncontrolled inflammation and impaired tissue repair, such as diabetes mellitus.

 
Abstract: In healt...Read More 

In health, inflammation serves to contain tissue injury and is normally self-limited. If excessive in amplitude and duration, inflammation is associated with the development of metabolic diseases like diabetes mellitus. Specialized pro-resolving lipid mediators (SPMs)–resolvins, protectins, and maresins–are novel autacoids that resolve inflammation, protect organs, and restore homeostasis. Via receptor-mediated signaling, SPM terminate neutrophil recruitment, counter-regulate pro-inflammatory mediators, and stimulate efferocytosis by macrophages and tissue remodeling. Here, we review SPM physiology and their roles in counter-regulating inflammation and restoring homeostasis in diabetes. We also present evidence for a novel intra-vascular biosynthetic pathway that is organ-protective, emphasizing SPM as potential therapeutic strategies for inflammation in metabolic diseases.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
3:05
Afternoon Networking Break
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
Diabetes Drug Discovery & Development 2017
What’s in the Pipeline: Pre-clinical & Clinical Strategies
Moderator: Denise Faustman, Harvard Medical School
3:35
Update on Phase II multi-dose BCG Clinical Trials for Reversal of Established Type 1 Diabetic Subjects
 
Denise Faustman
Denise Faustman
Director of Immunobiology; Associate Professor of Medicine
Massachusetts General Hospital; Harvard Medical School
About Speaker: Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She is currently leading a clinical trial program investigating the po... Read Full Bio 
 
 
Denise Faustman
Denise Faustman
Director of Immunobiology; Associate Professor of Medicine
Massachusetts General Hospital; Harvard Medical School
 
About Speaker:

Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She is currently leading a clinical trial program investigating the potential of the BCG vaccine as a disease reversal treatment for long-standing type 1 diabetes. Her research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness, the identification of interrupted T cell education through MHC class I, and the identification of autoimmune T cell sensitivity to TNF. For both autoreactive CD8 T cells she has identified the TNFR2 receptor as central and also the TNFR2 receptor for the expansion of beneficial Treg cells.  These achievements have earned her awards including the National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States, the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist,” and the Women in Science Award from the American Medical Women’s Association and Wyeth Pharmaceutical Company.  Dr. Faustman’s research has been highlighted in publications including Science, Nature, The Wall Street Journal, The New York Times, Los Angeles Times, The London Financial Times and Scientific American. She earned her MD and PhD from Washington University School of Medicine, in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital.

 

 
Abstract: The BCG vaccine represents the most c...Read More 

The BCG vaccine represents the most continuously used and safest vaccine in world history, first used over 100 years ago for tuberculosis prevention. Currently, 10 human clinical trials are testing repeat BCG vaccination in diverse forms of autoimmunity and allergies. Phase I study of the BCG vaccine, as two vaccines four weeks apart, in longstanding type 1 diabetics (T1D) reveals potential disease modulating effects after repeated BCG vaccinations, including death of autoreactive cells, transient and modest restoration of insulin secretion and induction of beneficial regulatory T cells (Tregs). This trial was designed for 22 weeks of intense monitoring. Global data on the efficacy of the BCG vaccine in autoimmunity, especially in new onset multiple sclerosis, suggests the full clinical effect of the vaccine develops after years;BCG prevents disease progression in Phase II multiple sclerosis trials, a benefit not mimicked by the standard of care. Based on the delay in full clinical effects of the BCG vaccine, 2 T1D clinical trials are underway to look for clinically meaningful improvements.   First, a long-term follow-up for 8 years after two BCG doses is underway. Second, a Phase II clinical trial using multi-dose BCG in longstanding T1D was initiated in June 2015 in 150 subjects with a five-year monitoring period. This double-blinded, placebo controlled immuno-interventional trial protocol was approved by the FDA and is unique in testing the efficacy of the BCG vaccine in long-term diabetic subjects (>15yrs) with small but detectable levels of C-peptide secretion.  Based on published Phase II clinical trial data of BCG in multiple sclerosis subjects, the therapeutic effects of this vaccine appear to improve over the passage of time; therefore, potential clinical benefits in the diabetes trial will be followed for 5 years. The primary endpoint of the Phase II BCG trail is decrease in HbA1c. The selection of BCG as an intervention in T1D is based on the protective host TNF response, including induction of Tregs, and potential long-term modulation of inflammatory profile of vaccinated subjects. All Phase II subjects are being monitored by RNAseq, epigenetics and Treg cell numbers and Treg signature gene expression to define the BCG mechanism.  Similar to the close pathogenic tuberculosis strain, BCG in humans systemically modifies the cytokine patterns and at least in culture, epigenetically turns on Treg cells for permanent reversal of self-reactivity.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
4:00
BPM51545 is a Novel First-in-Class Anti-Diabetic Biologic That Improves Glucose Metabolism in Skeletal Muscle
 
Pragalath Sundararajan
Pragalath Sundararajan
Scientist
BERG Health
About Speaker: Pragalath Sundararajan works as a Scientist in the Endocrinology program at BERG. He received his Bachelor of Technology in Biotechnology from Anna University, India and MS in Biotechnology from Northeastern University. Pragalath began his career at... Read Full Bio 
 
 
Pragalath Sundararajan
Pragalath Sundararajan
Scientist
BERG Health
 
About Speaker:

Pragalath Sundararajan works as a Scientist in the Endocrinology program at BERG. He received his Bachelor of Technology in Biotechnology from Anna University, India and MS in Biotechnology from Northeastern University.

Pragalath began his career at BERG five years ago and has worked on the validation of Diabetes drug targets identified by BERG’s proprietary Interrogative Biology® Platform. His work has contributed to BERG’s therapeutic pipeline which currently has multiple novel anti-diabetic biologic molecules that have progressed beyond the proof of concept phase and are in various stages of pre-clinical development. His current research efforts are focused on supporting the pre-clinical development of these molecules and in the identification of novel drug targets for Diabetes and other metabolic diseases.

 
Abstract: BERG&rsq...Read More 

BERG’s proprietary Interrogative Biology® Discovery platform was used to delineate distinct molecular signatures that drive the pathophysiology of diabetes and metabolic syndrome. Using this approach, we identified a novel anti-diabetic biologic, BPM51545, which improves glucose metabolism when delivered into skeletal muscle. A dose and time-dependent increase in the intracellular uptake of BPM51545 was observed upon treating cultured human skeletal muscle myotubes in vitro. The uptake of the enzymatically active form of BPM51545 significantly increased glucose uptake as well as glycolytic activity in myotubes and this effect was independent of insulin. In vivo, a nanoparticle system carrying a Skeletal Muscle Targeting Peptide (SMTP) was used to deliver BPM51545 to its site of action, in DIO and db/db mice. In both models, BPM51545 treatments significantly enhanced glucose tolerance without affecting body weight. Moreover, a consistent reduction in daily fed blood glucose levels was observed in db/db mice after 4 weeks of treatments. In addition, when combined with Rosiglitazone, BPM51545 treatments accelerated the time to attain blood glucose level normalization in db/db mice. This combination also lead to a significant reduction in body weight gain induced by Rosiglitazone alone treatments in db/db mice. Taken together, BPM51545 is a potent novel therapeutic biologic that can be used for treating diabetes and associated metabolic diseases.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
4:25
Diasome Pharmaceuticals’ 2017 Phase 2 and Phase 2b Clinical Trials Update
 
Robert Geho
Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
About Speaker: Robert Geho is co-founder and CEO of Diasome Pharmaceuticals, Inc., a privately-held developer of liver targeting systems for insulin and other drugs to treat diabetes.  Working alongside a team of nanotechnology formulation and protein chemistry ex... Read Full Bio 
 
 
Robert Geho
Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
 
About Speaker:

Robert Geho is co-founder and CEO of Diasome Pharmaceuticals, Inc., a privately-held developer of liver targeting systems for insulin and other drugs to treat diabetes.  Working alongside a team of nanotechnology formulation and protein chemistry experts, highly experienced clinical research professionals, and globally recognized investors, Robert is actively involved in the clinical development of Diasome’s Hepatocyte Directed Vesicle “HDV”) system.  HDV Insulin is Phase 3-enabled and is currently being tested in a multi-center Phase 2b study in patients with Type 1 diabetes.

 
Abstract: Diasome ...Read More 

Diasome Pharmaceuticals, Inc. is currently testing its proprietary Hepatocyte Directed Vesicle (“HDV”) technology in a randomized, double-blinded, six month dosing Phase 2b study in 150 subjects with Type 1 diabetes.  This study is designed to compare multiple clinical endpoints in subjects who receive either HDV + insulin lispro or lispro alone as their only pre-meal insulin therapy.  In addition, during the first half of 2017 Diasome is planning to initiate both a six week study of HDV Insulin in 40 Type 1 subjects focused on demonstrating improved glucose time in range (the “Good to Great” Study) and a first in man, randomized crossover design Phase 2 study of HDV Insulin in Type 1 subjects on insulin pumps.

 Read Less
ssclaas=mixsessionprlval=1Array ( [316] => 1 )
4:50
Networking Reception & Poster Session
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Day - 2 Thursday, April 6, 2017
 
7:30
Continental Breakfast
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Diabetes Partnering & Deal-Making 2017
Joint Plenary Session: Where do We Stand with Cell Therapy in Diabetes?
Moderator: Mark Zimmerman, Viacyte
8:30
Developing Cell Therapies for Diabetes
 
Mark Zimmerman
Mark Zimmerman
Vice President, Strategy and Business Development
ViaCyte
About Speaker: Mark Zimmerman received his bachelors in Biology from Syracuse University and his masters and doctorate in Biomedical Engineering from Rutgers University. Mark joined UMD-New Jersey Medical School as an Assistant Professor in 1986 and left in 1996 as... Read Full Bio 
 
 
Mark Zimmerman
Mark Zimmerman
Vice President, Strategy and Business Development
ViaCyte
 
About Speaker:

Mark Zimmerman received his bachelors in Biology from Syracuse University and his masters and doctorate in Biomedical Engineering from Rutgers University. Mark joined UMD-New Jersey Medical School as an Assistant Professor in 1986 and left in 1996 as an Associate Professor of Surgery with tenure. His research interests spanned musculoskeletal tissue engineering, sports medicine, trauma, and spine biomechanics and biomaterials.

Mark joined Johnson and Johnson in 1997 as a principal scientist/group leader and transitioned into regenerative medicine projects related to orthopaedic surgery, wound healing, vascular biology, and diabetes. Mark was appointed executive director of a Lifescan incubator, BetaLogics, in July 2002. BetaLogics transitioned to a Johnson and Johnson Internal Venture in 2004. The mission of BetaLogics was to discover and develop a cellular product to treat diabetes. Mark was appointed Venture Leader/Vice President of BetaLogics, a business unit of Janssen R&D LLC in 2009. Janssen completed a business transaction with ViaCyte in 2015 and merged the assets of BetaLogics into ViaCyte. Mark is currently seconded to ViaCyte and serves as the Vice President of Strategy and Business Development.

 
Abstract: ViaCyte&...Read More 

ViaCyte’s product candidates are based on the directed differentiation of pancreatic progenitor cells from human pluripotent stem cells. These pancreatic progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted, these cells are designed to further mature to the pancreatic endocrine cells, including beta cells, which secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte has two products in development. The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired hypoglycemia awareness. The PEC-Encap™ (also known as VC-01) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. This presentation will describe first-hand experience with the challenges and progress in developing pluripotent stem cell-derived products, including manufacturing and quality control, methods of delivery, clinical trials, and market opportunities.

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
8:55
Development of a Stem Cell Derived Pancreatic Islet Cell Therapy for Diabetes
 
Felicia Pagliuca
Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
About Speaker: Dr. Pagliuca currently serves as Vice President of Cell Biology Research and Development and is scientific co-founder of Semma Therapeutics. She leads cell-based research and development and plays a key role in supporting Semma's preclinical, regulat... Read Full Bio 
 
 
Felicia Pagliuca
Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
 
About Speaker:

Dr. Pagliuca currently serves as Vice President of Cell Biology Research and Development and is scientific co-founder of Semma Therapeutics. She leads cell-based research and development and plays a key role in supporting Semma's preclinical, regulatory, and manufacturing strategies for its cell therapy products. Felicia also works closely with Semma’s senior leadership on corporate development activities, including key collaborations and partnerships. Previously, Felicia was a postdoctoral fellow in Professor Doug Melton’s laboratory at the Harvard Stem Cell Institute. Felicia was part of the team in the Melton lab that discovered how to generate stem cell derived beta cells and published a seminal paper in Cell in 2014. She is an expert in stem cell biology and diabetes and one of the inventors of Semma Therapeutics’ key technologies. Felicia received a B.S. from Duke University and a Ph.D. from Cambridge University where she was a Marshall Scholar. She is currently on leave from Harvard Business School where she was a Kaplan Fellow.

 
Abstract: Semma Th...Read More 

Semma Therapeutics is a preclinical stage biotechnology company with the mission to transform the treatment of diabetes through development of stem cell derived pancreatic islets, including insulin-producing beta cells, to be used as a cell replacement therapy.   Diabetes results from the dysfunction and/or destruction of the insulin-producing beta cells in the pancreatic islet.  The development of replacement sources of beta cells, combined with effective methods of delivery back into the patient’s body, has the potential to “cure” the disease.  Recent breakthroughs have enabled the virtually unlimited production of replacement beta cells through pluripotent stem cell differentiation.  At Semma, we are focused on further optimization and innovation in differentiation technologies, manufacturing scale-up, and characterization of stem cell derived islets in preclinical studies in order to move into clinical trials.  In parallel, we are engineering innovative encapsulation solutions, using novel materials and device configurations, to solve the challenge of delivering and protecting these therapeutics from immune destruction.

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
9:20
Tolerogenic Therapy for Type 1 Diabetes: A Phase 2 Randomized Study of Autologous Regulatory T-cells Adolescents with Recent Onset T1DM
 
Douglas Losordo
Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
About Speaker: Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Clinical Professor of Medicine at  the New York University Langone Medical Center  and Adjunct Professor o... Read Full Bio 
 
 
Douglas Losordo
Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
 
About Speaker:

Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Clinical Professor of Medicine at  the New York University Langone Medical Center  and Adjunct Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Dr. Losordo’s career has been dedicated to patient care and to the development of novel therapeutics aimed at the reversal or repair of chronic conditions such as heart failure, critical limb ischemia, cancer and diabetes.

A native of Brooklyn, NY, he received his medical degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth’s Medical, Boston, Massachusetts, where he subsequently joined the faculty, working with the late Jeff Isner to develop a program in gene therapy and cell-based tissue repair. Dr. Losordo’s group has executed the full “translational medicine” paradigm: identifying potential therapeutic approaches in the laboratory, investigating these strategies in pre-clinical/IND-enabling models and designing and executing first-in-human and proof-of-concept clinical trials as the study sponsor/IND-holder. His work has included developing VEGF gene therapy for myocardial ischemia and diabetic neuropathy, CD34+ cell therapy for refractory angina, critical limb ischemia, severe claudication and coronary microvascular dysfunction and regulatory T cell therapy for autoimmune disease. Two of these candidates advanced to phase 3. At Caladrius Dr. Losordo has initiated a phase 2 study of autologous regulatory T cell therapy for new onset type 1 diabetes in children and recently received Japanese PMDA agreement on a study of CD34 cell therapy for critical limb ischemia targeting conditional approval under the new Japanese regulatory rules governing regenerative therapies. In addition to his own work Dr. Losordo has also mentored numerous scientists and physician-scientists from around the world who now have their own independent programs in translational research.

 
Abstract: T1DM in children is characterized by ...Read More 

T1DM in children is characterized by increased immune activation and a more aggressive clinical course compared to the adult population. Available evidence suggests that adoptive transfer of regulatory T-cells (Tregs) can slow disease progression and potentially lead to remission. Previous phase 1 clinical trials have demonstrated that expanded polyclonal Tregs are safe and well tolerated in both adults and children, supporting the development of a phase 2 trial to assess safety and efficacy of Treg therapy for T1DM in adolescents.

Caladrius Biosciences has launched a phase 2, double-blind, placebo-controlled, multi-center clinical trial to assess the safety and efficacy of autologous Tregs  to modify the T1DM disease course, including preservation of β-cell function and improvements in disease severity in adolescents (aged 8 to 17 years) with recent onset T1DM.

Approximately 111 subjects will be randomized to one of 3 treatment groups in a 1:1:1 ratio (placebo, 2.5 or 20 million Treg cells/kg BW). Key endpoints include the 2-hour and 4-hour Mixed Meal Tolerance Test (MMTT) stimulated C-peptide AUC at various time points through 24 months, daily dose of insulin use, severe hypoglycemia, and the percentage of subjects achieving partial or complete T1DM remission. Subjects will be followed for 2 years. A safety review has been conducted after the initial 19 subjects were followed for 3 months. An interim analysis is planned after approximately 50% of subjects complete the Week 26 visit. Extensive immune-profiling will be performed before and after Treg vs placebo infusion

This phase 2 study will advance insight into the safety and potential efficacy of adoptive transfer of Tregs to modify the T1DM disease course in children with recent onset T1DM as well as providing unprecedented insights into immune regulatory function.

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
9:45
Mesenchymal Stromal Cells as Cellular Therapeutics to Enhance Human Pancreatic Islet Transplantation in Type-1 Diabetes
 
John Campbell
John Campbell
Associate Director, Research, Development & Innovation
SNBTS, National Science Laboratory
About Speaker: Professor John Campbell is Associate Director of Research and Development at the Scottish National Blood Transfusion Service (SNBTS) in Edinburgh. He completed his PhD in Pathology at Edinburgh in 1995 on the immunopathogenesis of lymproliferative di... Read Full Bio 
 
 
John Campbell
John Campbell
Associate Director, Research, Development & Innovation
SNBTS, National Science Laboratory
 
About Speaker:

Professor John Campbell is Associate Director of Research and Development at the Scottish National Blood Transfusion Service (SNBTS) in Edinburgh. He completed his PhD in Pathology at Edinburgh in 1995 on the immunopathogenesis of lymproliferative disease, and has worked in the cellular therapy field for over 20 years in academic and industry positions. He is currently the national head of research for SNBTS and holds academic appointments at the Universities of Glasgow and Edinburgh. SNBTS has a substantial cellular therapy research programme, with over 40 full time scientists working on basic cellular function; translation of laboratory protocols to full GMP processes; and production of cellular therapeutics for treatment of patients. SNBTS has a dedicated, fully MHRA licensed, GMP cellular therapy production centre at the Scottish Centre for Regenerative Medicine. This GMP manufacturing and development capacity will be substantially increased when SNBTS moves to the Jack Copland Centre, Edinburgh, in early 2017. Cellular therapeutics in development and early phase clinical trials include, mesenchymal stromal cells, corneal limbal stem cells, macrophages for tissue repair and virus -specific T Lymphocytes.

 
Abstract: Islet tr...Read More 

Islet transplantation is of proven efficacy in subjects with Type 1 diabetes where glycaemic control is problematic, stabilizing glycaemic control and restoring awareness of hypoglycaemia where this has been compromised. However, long term graft survival remains poor and patients typically require two to three islet transplants. Innate and adaptive immune responses contribute to early and ongoing graft attrition. Therapeutic strategies to improve graft function are urgently needed. Ideally, a therapeutic strategy would modulate the inflammatory and immune response and enhance engraftment of islets. Mesenchymal stromal cells (MSCs) are multipotent cells found in the majority of tissues and have been shown to support regeneration of tissues by supporting blood vessel formation through a broad spectrum of growth factors and extracellular matrix secreted. This tissue building function is accompanied by the ability to suppress T cell responses and modulate inflammatory infiltration. We have investigated the ability of GMP-grade human MSC to support human Islet engraftment and function in vivo pre-clinical models. In this presentation we will discuss the properties of MSC from different source tissues and how they can be used to support and improve islet graft function.

Learning outcomes:
– Understanding the impact of islet transplantation on the health of patients with severe Type-1 Diabetes
– Understanding the function of Mesenchymal Stromal Cells as cellular therapeutics, including the challenges of GMP manufacturing
– In vivo models of human islet transplantation – what can be learned and what are the limitations
– Measuring the improvement in transplant function when co-transplanted with cellular therapeutics

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
10:10
Morning Networking Break
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
11:25
Lunch on Your Own
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Diabetes Partnering & Deal-Making 2017
Devices and Digital Aids in Diabetes Management
Moderator: Nathaniel Heintzman, Dexcom
1:30
Advances in Automation of Glucose Management In Diabetes Mellitus
 
Steven Russell
Steven Russell
Assistant Professor of Medicine
Harvard Medical School
About Speaker: ... Read Full Bio 
 
 
Steven Russell
Steven Russell
Assistant Professor of Medicine
Harvard Medical School
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
1:55
Evolution of Glucose Monitoring in Diabetes Management
 
Laura Brandner
Laura Brandner
Manager of Global Software Innovation
Abbott
About Speaker: Laura Brandner manages Product Management for Digital Platforms at Abbott Diabetes Care. Laura has a Bachelor of Science in Chemical Engineering from Purdue University and a Master’s in Business Administration from the Haas School of Business at U... Read Full Bio 
 
 
Laura Brandner
Laura Brandner
Manager of Global Software Innovation
Abbott
 
About Speaker:

Laura Brandner manages Product Management for Digital Platforms at Abbott Diabetes Care.

Laura has a Bachelor of Science in Chemical Engineering from Purdue University and a Master’s in Business Administration from the Haas School of Business at UC Berkeley.

She began her career at Abbott and has spent time in various Abbott divisions working in engineering, project management, planning and forecasting, innovation, and now software product management.

In her current role, she manages innovative software products from ideation to launch including product design and definition, positioning/branding, customer service, legal, data privacy, regulatory, quality, and product lifecycle management.

 
Abstract: Today, 4...Read More 

Today, 415 million people around the world live with diabetes. Given this global epidemic, there is a huge need for access to the latest technology, tools, and treatments to help people manage their condition so that all people with diabetes are able to enjoy a vigorous, active life. This presentation will focus on the evolution of diabetes management, specifically on how technology has evolved and the impact it has on people living with diabetes.

For several decades, blood glucose monitors only gave patients point-in-time data, and were bulky and cumbersome to use. Eventually, continuous glucose monitoring gave patients access to a fuller picture of their glucose levels. New technologies such as Abbott’s wearable glucose sensing technology is designed to be a new and even simpler way of using sensor technology—easier, less burdensome and considerably more accessible. The technology also provides patients and healthcare professionals’ glucose trend data and insights in a visual method, helping them make better informed decisions around medication, nutrition, etc.

The advancement of diabetes technology is transforming how people manage their diabetes on a day-to-day basis.  In the past few years, there has also been a significant rise in the development of mobile app and software technologies to help streamline and improve diabetes management. People living with diabetes are now able to be much closer to their glucose levels, patterns, and insights, and have the ability to share these insights with their healthcare professional and/or a caregiver.

Benefits/Highlights of Presentation:

  • Global diabetes landscape
  • Unmet needs of people living with diabetes (and the people surrounding them)
  • How traditional glucose monitoring has been done for decades
  • What continuous glucose monitoring systems are
  • How CGMs and other diabetes technology has evolved today
 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
2:20
Data@Dexcom: CGM Technology, IoT Connectivity, and the Drive to Insight Delivery in Diabetes Care
 
Nathaniel Heintzman
Nathaniel Heintzman
Director, Partner Portfolio
Dexcom
About Speaker: Nathaniel Heintzman is the Senior Manager of Data Partnerships at Dexcom Inc, where he leads efforts to support and expand the diabetes innovation ecosystem. Prior to joining Dexcom in early 2014, he directed the Diabetes Informatics + Analytics Lab ... Read Full Bio 
 
 
Nathaniel Heintzman
Nathaniel Heintzman
Director, Partner Portfolio
Dexcom
 
About Speaker:

Nathaniel Heintzman is the Senior Manager of Data Partnerships at Dexcom Inc, where he leads efforts to support and expand the diabetes innovation ecosystem. Prior to joining Dexcom in early 2014, he directed the Diabetes Informatics + Analytics Lab (DIAL) at the University of California, San Diego (UCSD), where he served as faculty in the School of Medicine’s Division of Biomedical Informatics. Heintzman also has a long history of diabetes advocacy, including his founding role in Insulindependence and volunteering for other diabetes advocacy organizations.

Heintzman received his PhD in Biomedical Science from UCSD and his BA in Biochemistry and Molecular Genetics at Gustavus Adolphus College (St Peter, Minn), and his graduate and postdoctoral research in genomics and bioinformatics was published in Nature. He lives in San Diego, California with his wife, and enjoys spending his spare time surfing, playing bass and keyboard in his rock cover band, and gardening.

ssclaas=mixsessionprlval=1Array ( [317] => 1 )
2:45
Tackling Diabetes: One Monster at a Time
 
Scott Johnson
Scott Johnson
Communications Lead
mySugr GmbH
About Speaker: Scott is an experienced patient advocate. He works with a wide range of stakeholders across the healthcare environment to help them establish effective communication with the patient community. His expertise in the diabetes social media space is reco... Read Full Bio 
 
 
Scott Johnson
Scott Johnson
Communications Lead
mySugr GmbH
 
About Speaker:

Scott is an experienced patient advocate. He works with a wide range of stakeholders across the healthcare environment to help them establish effective communication with the patient community. His expertise in the diabetes social media space is recognized worldwide and he advises organizations within the healthcare, food, and consumer goods industries.

Today he is Communications Lead, USA for mySugr and Patient Pathways Lead in the Diabetes Division of Delta Project Management. He manages a long-standing and award-winning blog “Scott's Diabetes” that reaches hundreds of thousands of people annually.

Scott is also a member of the Children with Diabetes faculty where he develops educational curriculums and content for the Friends for Life annual conference and regional events. He is on the Executive Committee of the Board of Directors for the Diabetes Hands Foundation, the Board of Directors for the Diabetes Community Advocacy Foundation, and is a founding member of Partnering for Diabetes Change, a coalition of people living with diabetes and industry representatives working to support underserved communities. He is interested in how these types of interactions including peer-to-peer support impact patient outcomes and routinely presents his work.

 
Abstract: Data pla...Read More 

Data plays a key role in diabetes management. But it doesn’t belong in people’s heads, on paper logbooks, or spread across multiple diabetes devices. As the world’s most popular digital diabetes platform, mySugr has become the central solution for nearly one million people and counting. Learn more about the story of mySugr, some keys to their success, and what’s next for this market leading digital diabetes company.

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
3:10
Afternoon Networking Break
ssclaas=parallelprlval=0Array ( [317] => 4 )
Panel: Treating Diabetes in 2020: Beyond Insulin, What?
Moderator: Alexander (Zan) Fleming, Kinexum
Array ( [2806] => Array ( [sheduleid] => 2806 [new_session] => 1 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491491400 [next] => 1491497700 )[2807] => Array ( [sheduleid] => 2807 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491491400 [next] => 1491497700 )[2808] => Array ( [sheduleid] => 2808 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491491400 [next] => 1491497700 )[2809] => Array ( [sheduleid] => 2809 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491491400 [next] => 1491497700 ))
3:55
Alexander (Zan) Fleming
Alexander (Zan) Fleming
President & Chief Exective Officer
Kinexum
 
Alexander (Zan) Fleming
Alexander (Zan) Fleming
President & Chief Exective Officer
Kinexum
 
About Speaker:

Dr. Alexander Fleming received his M.D. and internal medicine training from Emory, fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow. From 1986-98 Dr. Fleming served as reviewer and supervisory medical officer at the US Food and Drug Administration.  He acquired extensive clinical experience and regulatory responsibility in the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, orphan drug indications, and reproductive indications.  He led reviews of landmark approvals including those of the first statin, insulin analog, metformin, PPAR-agonist, and growth hormone for non-GH deficiency indications. He was responsible for the regulation of the earliest biotech products including human insulin and growth hormone.  He helped to shape a number of FDA policies and practices related to therapeutic review and regulatory communication.

His regulatory and technical expertise has been requested in numerous international settings including the World Health Organization, where he was assigned during 1991-92.  Dr. Fleming was a member of the expert working groups on Good Clinical Practices and General Considerations for Clinical Trials of the International Conference on Harmonization (ICH) and participated on other ICH committees including the Common Technical Document working group. 

He was also the founder and editor in chief of the Virtual Journal of Drug Evaluation, of FDA's Center for Drug Evaluation and Research (CDER), a major contributor to FDA's Good Review Practice (GRP) initiative, and chair of the committee responsible for education and training at CDER.   He conceived and led the first FDA pilot project to utilize the internet for regulatory communication. Dr. Fleming is lead author of the book, “Optimizing Development of Therapies for Diabetes.” He has frequently published scientific articles and book chapters, the most recent chapter, Regulatory Considerations for Early Clinical Development, is in Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, published by Springer in January 2015.  He has been a member of number corporate and professional society advisory boards.  The most recent is the joint European Association for the Study of Diabetes and American Diabetes Association working group on insulin pump safety. 

Dr. Fleming founded Kinexum, a strategic advisory firm in 2003 and continues to serve as its chief executive officer.

Riccardo Perfetti
Riccardo Perfetti
Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi
Sanofi Diabetes & Cardiovascular Business Unit
 
Riccardo Perfetti
Riccardo Perfetti
Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi
Sanofi Diabetes & Cardiovascular Business Unit
 
About Speaker:

Riccardo Perfetti, MD, PhD

Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi.

Riccardo Perfetti is the Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi. He trained as an endocrinologist at La Sapienza University, Rome, where he also achieved a PhD in molecular endocrinology in a joint training program with the Johns Hopkins University. He spent ten years at the National Institutes of Health (NIH), Bethesda, working as a Senior Research Fellow and Senior Staff Scientist. In the following eight years Dr Perfetti held a number of clinical, teaching and research positions at the Cedars-Sinai Medical Center and at University of California Los Angeles, where he directed the clinical diabetes program and the basic science diabetes research laboratory. Prior to joining Sanofi in 2007, he held several positions at Amgen Inc, including Director, Department of Medical Sciences within the Translation Medicine Department and Global Development Lead with the General Medicine Development Department. In his current role, he is responsible for the clinical evidence generation strategy for approved and development programs. Dr Perfetti has published numerous articles and is a reviewer for several journals.

Aaron Schwartz
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
 
Aaron Schwartz
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
 
About Speaker:

Aaron is a Director in Novo Nordisk’s R&D Innovation Sourcing team.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergrad degree in biology from the University of Chicago and a Masters degree in biology from MIT.

Brian Bloomquist
Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
 
Brian Bloomquist
Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
 
About Speaker:

Brian has been at Eli Lilly since April 2006 where his role within the Diabetes External Innovation group is to lead the evaluation of external partnering opportunities in diabetes and endocrine disease for technical merit and portfolio fit.  Prior to coming to Lilly, he spent 11 years in the Metabolic Disorders group at Bayer Pharmaceuticals where his laboratory was engaged in obesity drug discovery and he held multiple leadership positions in the management of the Obesity Research portfolio.  Brian completed his post-doctoral studies at The Johns Hopkins University School of Medicine where he studied dopaminergic signaling in the laboratory of Dr. Betty Eipper following his graduate studies at Purdue University where he investigated Drosophila photoreceptor signal transduction under Dr. William Pak and his thesis was awarded the first A.H. Ismail Interdisciplinary Dissertation Award.  Dr. Bloomquist has been a speaker or panelist at multiple conferences including Bio-Europe, GTC Bio, Mass Bio, Ausbiotech, and the Queensland Investment Forum, has been cited in Close Concerns, a leading diabetes and obesity healthcare information company, is an inventor on a number of patents, and is the author of multiple peer-reviewed publications, including an article highlighted on the cover of the journal Cell. 

ssclaas=mixsessionprlval=1Array ( [317] => 1 )
4:55
Day 2 Concludes
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Day - 3 Friday, April 7, 2017
 
7:30
Continental Breakfast
ssclaas=parallelprlval=0Array ( [317] => 6 )
Panel: Current Trends and Future Projections for Investments
Moderator: John Brooks III, Healthcare Capital LLC
Array ( [1750] => Array ( [sheduleid] => 1750 [new_session] => 1 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491550200 [next] => 1491556500 )[1756] => Array ( [sheduleid] => 1756 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491550200 [next] => 1491556500 )[1757] => Array ( [sheduleid] => 1757 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491550200 [next] => 1491556500 )[2395] => Array ( [sheduleid] => 2395 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491550200 [next] => 1491556500 )[2400] => Array ( [sheduleid] => 2400 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491550200 [next] => 1491556500 )[2401] => Array ( [sheduleid] => 2401 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491550200 [next] => 1491556500 ))
8:30
John Brooks
John Brooks
Managing Director
Healthcare Capital LLC
 
John Brooks
John Brooks
Managing Director
Healthcare Capital LLC
 
About Speaker:

John L. Brooks III is the Managing Director of Healthcare Capital LLC, which advises early-stage life sciences companies. Healthcare Capital specializes in advancing disruptive and innovative solutions in healthcare, especially in obesity, pre-diabetes, and diabetes. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations.

Mr. Brooks is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.

Mr. Brooks is a well-known life sciences executive. He has co-founded seven life sciences companies, including Insulet (PODD), a disruptive insulin delivery company. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm.

Prior to that, Mr. Brooks was a senior medical device executive at Pfizer, and a senior manager at Arthur Andersen & Co. in Boston, MA, where he focused on early stage companies.

A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant.

Jonathan Behr
Jonathan Behr
Managing Director
JDFR
 
Jonathan Behr
Jonathan Behr
Managing Director
JDFR
 
About Speaker:

Jon joined the T1D Fund from Partners Healthcare Innovation, where he was a Market Sector Leader and Executive in Residence, driving technology translation from research hospitals affiliated with Harvard Medical School. He previously held senior venture creation roles including Vice President of New Ventures for Enlight Biosciences and Principal at PureTech Ventures (LON:PRTC). Jon has co-founded and supported seven companies (including holding C-level operating, business development and board director positions) and managed alliances with top pharmaceutical companies. He earned his Ph.D. at Massachusetts Institute of Technology as a Howard Hughes fellow and his B.S. from Rice University.

Nandan Padukone
Nandan Padukone
Senior Vice President, Innovation
Joslin Diabetes Center
 
Nandan Padukone
Nandan Padukone
Senior Vice President, Innovation
Joslin Diabetes Center
 
About Speaker:

Dr. Nandan Padukone heads up Joslin Innovation as Senior Vice President and Global Head, which he helped launch as a business center of Joslin Diabetes Center to create strategic relationships with industry, governments and healthcare providers to leverage Joslin’s world-leading expertise in diabetes-directed research, education and clinical care. His research interests include redesigning health care delivery models to optimize outcomes for people with diabetes. He has created more than 25 strategic alliances with pharmaceutical, biotechnology, device and care delivery organizations at the Joslin Diabetes Center in less than 4 years.

Dr. Padukone has 17 years in biotechnology management and entrepreneurial ventures involving diagnostics (Nuvera), therapeutics (Altus Pharma), bioinformatics (Silico Insights), and renewable energy (NREL). He helped launch Nuvera Biosciences as founding CEO in 2005, a venture focused on cancer therapy and pharmacogenomics, in collaboration with MD Anderson Cancer Center. At Nuvera, he was responsible for venture capitalization, product validation, and business development, and forged alliances with cancer centers and diagnostic companies in US and Europe. He actively engaged with regulatory agencies, healthcare organizations, and patient advocacy groups. 

Previously, Dr. Padukone was the founder and CEO of Silico Insights, a bioinformatics company launched in 2000, and served previously as Director of Technology and Board Member at Altus Biologics, a spin-out venture of Vertex Pharmaceuticals. He also led scientific teams at the National Renewable Energy Laboratory (NREL) and led industrial partnerships in development of bioethanol and biodegradable polymers.

Dr. Padukone holds a Ph.D. in Biotechnology and Biochemical Engineering from North Carolina State University, an MBA from University of Denver, MS from SUNY Buffalo, and a B. Tech. from IIT, Mumbai, India.

Mostafa Analoui
Mostafa Analoui
Executive Director
UCONN Ventures
 
Mostafa Analoui
Mostafa Analoui
Executive Director
UCONN Ventures
 
About Speaker:

Mostafa Analoui, Ph.D., is Executive Director of UCONN Ventures. Previously, he was Head of Healthcare and Life Sciences at Livingston Securities (New York, NY) with investment focus in private and public companies in biotech, medtech and healthcare services. Prior to that he was the Senior Director at Pfizer Global Research and Development. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies.

While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.

In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and OECD. Dr. Analoui has authored over 130 publications, including journal articles, book chapters and technical reports.  Dr. Analoui is currently Adjust Professor at Brown University (Providence, RI), Northeastern University (Boston, MA) and University of Connecticut (Storrs, CT). He is also senior member of IEEE, SPIE, and RSNA.

He was Chairman of the Board of VirtualScopics (Nasdaq: VSCP) and currently serves as board member of Calando Pharmaceutical (Nasdaq: ARWR), BEACON (Biomedical Engineering Alliance and Consortium) and NanoBusiness Commercialization Association.

Benjamin Conway
Benjamin Conway
Managing Director, Life Sciences
Consilium Partners
 
Benjamin Conway
Benjamin Conway
Managing Director, Life Sciences
Consilium Partners
 
About Speaker:

Benjamin Conway is a managing director and head of the life sciences group for the Boston-based investment bank Consilium Partners.   Ben has over 20 years' experience in life science banking, with transaction experience in the biopharma and specialty pharma, medical device and diagnostics sectors as well as the ancillary service sectors.  Prior to joining Consilium, he was managing director of Johnston Blakely & Company, a boutique life science investment bank he founded in 2002 and subsequently acquired by the CMC Consulting Group AG.  Previously, Ben was group head of biotechnology investment banking at Adams, Harkness & Hill (today Canaccord Genuity), where he led the Adams, Harkness group to a top ranking for completed middle market M&A transactions.  Ben's experience also includes positions with Abbott Laboratories and Bain & Company. 

Richard Berenson
Richard Berenson
Chief Executive Officer
Thermalin Diabetes
 
Richard Berenson
Richard Berenson
Chief Executive Officer
Thermalin Diabetes
 
About Speaker:

Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey & Company consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Diabetes Partnering & Deal-Making 2017
Partnering and Licensing Opportunities
Moderator: Aaron Schwartz, Novo Nordisk
9:15
Novo Nordisk Partnering Focus - 2017
 
Aaron Schwartz
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
About Speaker: Aaron is a Director in Novo Nordisk’s R&D Innovation Sourcing team.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining... Read Full Bio 
 
 
Aaron Schwartz
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
 
About Speaker:

Aaron is a Director in Novo Nordisk’s R&D Innovation Sourcing team.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergrad degree in biology from the University of Chicago and a Masters degree in biology from MIT.

 
Abstract: Novo Nor...Read More 

Novo Nordisk is a global biopharma with products in diabetes, obesity, haemophelia, and growth disorders.  Currently Novo Nordisk only sells biologic drugs.  This talk will provide a corporate  overview and highlights of  the commercial needs and areas of scouting interest.

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
9:40
Leveraging the Public Private Partnership Space
 
MaryJulia Brosnan
MaryJulia Brosnan
Director, External Collaborations and Scientific Alliances
Pfizer
About Speaker: ... Read Full Bio 
 
 
MaryJulia Brosnan
MaryJulia Brosnan
Director, External Collaborations and Scientific Alliances
Pfizer
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
10:05
Morning Networking Break
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Diabetes Partnering & Deal-Making 2017
Biotech Showcase: Emerging Pipelines
Moderator: Aaron Schwartz, Novo Nordisk
10:35
3rd Generation Drugs & Precision Medicine
 
Richard Berenson
Richard Berenson
Chief Executive Officer
Thermalin Diabetes
About Speaker: Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey & Company consultant, Rick received a JD-MBA from Harva... Read Full Bio 
 
 
Richard Berenson
Richard Berenson
Chief Executive Officer
Thermalin Diabetes
 
About Speaker:

Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey & Company consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

 
Abstract: In an in...Read More 

In an increasingly cost-conscious healthcare world, expensive, new, 3rd generation drugs with only incremental net therapeutic advantage can provide poor returns on drug development investments.  However, for indications where precise disease management has medical benefit, developing 3rd generation drugs designed to reduce adherence burden and enable new delivery/control methods can offer significant economic opportunity.  Mr. Berenson will discuss Thermalin’s pipeline of next generation insulin analogs in this context.  Attendees will learn: (1) how the burden of insulin therapy today leads to poor outcomes, (2) how different types of burden affects different patient populations, (3) strategies for lowering that burden in the future, (4) limitations of current insulin formulations, (5) how Thermalin’s pipeline seeks to overcome those limitations.

 Read Less
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
11:00
Immune Modulatory Biomaterials for Cell-based Therapies
 
Omid Veiseh
Omid Veiseh
Founding Scientist and Head of Innovation
Sigilon
About Speaker: Dr. Omid Veiseh is the Founding Scientist and Head of Innovation at Sigilon. He also holds academic position as an Assistant Professor and CPRIT Scholar in Cancer Research in Department of Bioengineering at Rice University. Dr. Veiseh has over a deca... Read Full Bio 
 
 
Omid Veiseh
Omid Veiseh
Founding Scientist and Head of Innovation
Sigilon
 
About Speaker:

Dr. Omid Veiseh is the Founding Scientist and Head of Innovation at Sigilon. He also holds academic position as an Assistant Professor and CPRIT Scholar in Cancer Research in Department of Bioengineering at Rice University. Dr. Veiseh has over a decade of experience developing biotechnologies for clinical application. He received a dual Ph.D. in Materials Science, Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at Koch Institute for Integrative Cancer Research at MIT and Harvard Medical School. Over the course of his career he has authored, or co-authored more than 50 peer-reviewed publications including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, Nature Reviews Drug Discovery, and is an inventor on 20 pending or awarded patents, many of which have been licensed for commercialization by 3 separate biotechnology companies. He has received numerous awards and fellowships including: NSF Integrative Graduate Education and Research Training (IGERT) Fellowship, NIH T32 Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship, Juvenile Diabetes Research Foundation Postdoctoral Fellowship, DOD/CDMRP Breast Cancer Research Program Postdoctoral Fellowship, and DOD/CDMRP Visionary Postdoctoral Fellowship, a Young Investigator Award from the Arthritis National Research Foundation (ANRF), and most recently, he was awarded a $2 million CPRIT Scholar In Cancer Research Award from state of Texas.

 
Abstract: Immune c...Read More 

Immune cell recognition of implanted biomedical devices initiate a cascade of inflammatory events that result in collagenous encapsulation of implanted materials which leads to device failure. These adverse outcomes emphasize the critical need for biomaterials that do not elicit foreign body responses. One prime example for the use of this technology is with the development of a bioartificial pancreas for the treatment of patients suffering from diabetes. Immunoisolation of insulin producing cells with porous biomaterials provide an immune barrier that is a potentially viable treatment strategy for Type1 diabetic patients. However, clinical implementation has been challenging due to host immune responses to implanted materials. To address this challenge, we have focused our efforts on the development of improved biomaterials for the use in pancreatic islet cell transplantation.

To enable the discovery of novel superbiocompatible biomaterials we have developed a high throughput pipeline for the synthesis and evaluation of >1000 material formulations and prototype devices. Here, we describe combinatorial methods we have developed for covalent chemical modification and in vivo evaluation of alginate based hydrogels. Using these methods, we have created and screened the first large library of hydrogels, and identified leads that are able to resist foreign body reactions in both rodents and nonhuman primates. These formulations have been used to generate optimized porous alginate hydrogels fabricated with tuned geometries to enhance biocompatibility. We have identified a lead alginate derivative and capsule formulation geometry that shows minimal recognition by macrophages and other immune cells, and almost no visible fibrous deposition in rodents, and up to at least six months in nonhuman primates. Significantly, our lead formulation has enabled us to achieve the first long term glycemic correction of a diabetic, immune competent animal model with human embryonic stem-cell derived islet cells, encapsulated using our novel superbiocompatible, chemically modified alginate formulation.

 Read Less
ssclaas=parallelprlval=0Array ( [317] => 3 )
Round Table 1: Street Light Effect: Diabetology Research Trapped at the Level of Methodology and Dominant Paradigm, “Science Bubbles”
Chair: Bruno Doiron, Faculty Member, Medicine - Diabetes Division, University of Texas
Array ( [1794] => Array ( [sheduleid] => 1794 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => sessiontype [prev] => 1491562800 [next] => 1491567300 )[3101] => Array ( [sheduleid] => 3101 [new_session] => 1 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491562800 [next] => 1491567300 )[3105] => Array ( [sheduleid] => 3105 [new_session] => 1 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491562800 [next] => 1491567300 ))
11:25
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
12:15
Lunch Provided by GTCbio
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Diabetes Partnering & Deal-Making 2017
Panel: Patient Entrepreneur
Moderator: Satish Medicetty, GTCbio
1:40
 
Charles O'Connell
Charles O'Connell
Founder and CEO
Fitscript
About Speaker: Charlie is the Founder and CEO of Fitscript, a company dedicated to helping people living with diabetes through exercise, education and technology. Fitscript’s GLUCOSEZONE program is a digital health solution that provides exercise guidance based o... Read Full Bio 
 
 
Charles O'Connell
Charles O'Connell
Founder and CEO
Fitscript
 
About Speaker:

Charlie is the Founder and CEO of Fitscript, a company dedicated to helping people living with diabetes through exercise, education and technology. Fitscript’s GLUCOSEZONE program is a digital health solution that provides exercise guidance based on real-time glucose levels, captured from wearable devices and glucometers. The GLUCOSEZONE program provides real-time and algorithmic based guidance, access to CDE's and digital health coaches, and offers live stream programming as well as programming for at home, gym, or outside; on the end users digital platform of choice. To date, over 400,000 people around the globe have benefited from GLUCOSEZONE digital programming.

Recognizing a lack of guidance and support related to exercise and diabetes, Charlie founded FITSCRIPT.COM in September of 2012 to help others with diabetes reach their fitness goals through structured exercise guidance, support, and training. In the fall of 2013, Charlie opened the FITSCRIPT Diabetes Training Center, the world’s first exercise clinic dedicated exclusively to diabetes prevention and management.

Diagnosed with Type 1 diabetes at Yale New Haven Hospital in the fall of 1996, Charlie is a graduate of the University of Pennsylvania (’02) where he was a two-sport varsity athlete (Football and Track and Field), as well as high school All-American in Track and Field. Before founding FITSCRIPT, Charlie worked in business development for a successful start-up software company.

ssclaas=mixsessionprlval=1Array ( [317] => 1 )
1:50
 
Shantanu Gaur
Shantanu Gaur
Co-Founder & Chief Scientific Officer
Allurion Technologies
About Speaker: Dr. Shantanu Gaur is the Founder and Chief Scientific Officer of Allurion Technologies. Together with his partners, Shantanu has overseen Allurion’s research and development, fundraising, and clinical programs. Shantanu founded Allurion in 2009 to ... Read Full Bio 
 
 
Shantanu Gaur
Shantanu Gaur
Co-Founder & Chief Scientific Officer
Allurion Technologies
 
About Speaker:

Dr. Shantanu Gaur is the Founder and Chief Scientific Officer of Allurion Technologies. Together with his partners, Shantanu has overseen Allurion’s research and development, fundraising, and clinical programs. Shantanu founded Allurion in 2009 to develop disruptive devices for the weight loss industry that are more effective than diet and exercise but safer, cheaper, and more accessible than weight loss surgery. Allurion’s flagship product—the Elipse™ Balloon—is the world’s first procedureless gastric balloon for weight loss and is now available for commercial sale internationally.

Shantanu also serves as a board member for Genetic Alliance, a non-profit committed to putting the participant back at the center of healthcare. He has overseen the development of tools and initiatives that utilize crowdsourcing and open science principles that have transformed how drugs are discovered, clinical trials are run, and healthcare data is accessed and shared.

Shantanu is the lead inventor on several US and international patents and has authored multiple peer-reviewed publications. He has been invited to speak on the Elipse Balloon, obesity, and medical device innovation at several worldwide congresses and has also spoken widely on the use of crowdsourcing to make research more efficient and participant-centric. Shantanu graduated summa cum laude with a B.S. in Biology from Harvard College and with an M.D. from Harvard Medical School where he was Paul & Daisy Soros Fellow. He lives in Cambridge, MA with his wife Neha.

ssclaas=parallelprlval=0Array ( [317] => 2 )
Panel: Patient Entrepreneur

Array ( [1761] => Array ( [sheduleid] => 1761 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491573000 [next] => 1491574200 )[2810] => Array ( [sheduleid] => 2810 [new_session] => 0 [single_conf] => 0 [cfid] => 317 [schedule_type] => speakerslot [prev] => 1491573000 [next] => 1491574200 ))
2:00
Robert Geho
Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
 
Robert Geho
Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
 
About Speaker:

Robert Geho is co-founder and CEO of Diasome Pharmaceuticals, Inc., a privately-held developer of liver targeting systems for insulin and other drugs to treat diabetes.  Working alongside a team of nanotechnology formulation and protein chemistry experts, highly experienced clinical research professionals, and globally recognized investors, Robert is actively involved in the clinical development of Diasome’s Hepatocyte Directed Vesicle “HDV”) system.  HDV Insulin is Phase 3-enabled and is currently being tested in a multi-center Phase 2b study in patients with Type 1 diabetes.

ssclaas=mixsessionprlval=1Array ( [317] => 1 )
2:10
 
Victor Chapela
Victor Chapela
Chief Executive Officer and Co-Founder
Suggestic
About Speaker: Victor Chapela is the cofounder and CEO of Suggestic, a Silicon Valley startup that uses artificial intelligence and augmented reality to transform food into medicine. It optimizes diets by finding which sequences of food work best for each individua... Read Full Bio 
 
 
Victor Chapela
Victor Chapela
Chief Executive Officer and Co-Founder
Suggestic
 
About Speaker:

Victor Chapela is the cofounder and CEO of Suggestic, a Silicon Valley startup that uses artificial intelligence and augmented reality to transform food into medicine. It optimizes diets by finding which sequences of food work best for each individual. Its fully automated nutrition coach makes it as easy as possible to make the best food choices, anytime, everywhere.

Victor is a serial entrepreneur with over 20 years of experience. During this time, he has founded and sold three technology companies. His main expertise lies within the areas of machine learning and artificial intelligence.

ssclaas=mixsessionprlval=1Array ( [317] => 1 )
Moderated Discussion
ssclaas=mixsessionprlval=1Array ( [317] => 1 )
3:30
Conference Concludes